Shareholder Information

Overview

MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on proprietary genetic, epigenetic and other complex molecular technologies.

MDxHealth is dedicated to providing highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment while improving healthcare economics for payers and providers.

An overview of the most recent information about MDxHealth can be found in the company’s periodic corporate presentation slides and can be download here. Corporate Presentation 2021

MDxHealth is listed on the Euronext and on NASDAQ under the ticker symbol MDXH.

MDxHealth has been listed on Euronext since 2006 and on NASDAQ since 2021. There is only one class of shares in the company (common shares) and all shares have the same rights and voting representation. Other than American Depository Shares (ADS) listed on NASDAQ (each representing ten common shares) and stock options issued to employees, directors, and some consultants, there are no other financial instruments issued by the company.

Corporate Governance Charter

MDxHealth attaches great value to corporate governance practices. On April 14, 2021, our board of directors approved the current version of MDxHealth’s Corporate Governance Charter. The Charter has been drafted in accordance with the principles of Belgian. Code on Corporate Governance.

The full text of MDxHealth’s Corporate Governance Charter can be download here: English

Code of Ethics

The full text of MDxHealth’s Code of Ethics can be downloaded here: English

Dealing Code

As a listed company, MDxHealth must comply with rules governing insider trading. The company’s dealing code can be found here: English

Articles of Association

The Articles of Association are periodically updated. The latest version can be found here: English I Français

Share capital history

The history of the share capital issuance since the inception of the company can be found here:

History of Share Capital (Jan. 26, 2021)

Transparency Declarations of the largest shareholders

The table below provides an overview of the shareholders that filed a notification with MDxHealth SA pursuant to applicable transparency disclosure rules. Although the applicable transparency disclosure rules require that a disclosure must be made by each person passing or falling under one of the relevant thresholds, it is possible that the information below in relation to a shareholder is no longer up-to-date. The percentages of voting rights mentioned in the table have been calculated on the basis of the currently outstanding shares.

SHAREHOLDER (OR PARTY REPRESENTING SHAREHOLDERS)	MVM PARTNERS LLP	BLEICHROEDER LP	BIOVEST NV	VALIANCE ASSET MANAGEMENT	SCORPIAUX BVBA
% OF OUTSTANDING SHARES	22.23%	15.25%	9.36%	12.30%	4.26%
SITUATION AS OF	May 15, 2020	Nov.19, 2021	Jan. 26, 2021	May 15, 2020	May 15, 2020
NOTIFICATION RECEIVED	May 18, 2020	Nov. 22, 2021	Feb. 1, 2021	May 21, 2020	June 2, 2020
NOTIFICATION FORM	Click here to view form	Click here to view form	Click here to view form	Click here to view form	Click here to view form

*Percentage calculated as per the date of the relevant transaction and taking into account the total number of outstanding shares as per such date

Each natural or legal person acquiring or transferring MDxHealth’s shares is required to notify MDxHealth and the Financial Services and Markets Authority (FSMA) each time their shareholding crosses a threshold of three percent (3%) of the total number of outstanding shares (the denominator). Such notification is also required each time, as a result of an acquisition or transfer a threshold of five percent (5%) and a multiple of five percent (5%) is crossed. Complete information regarding this requirement is found in Article 14 of MDxHealth’s articles of association.

The transparency notifications should be reported within 5 business days of crossing the threshold by following the procedures outlined on the FSMA website found here.

A copy of the transparency notification should also be emailed and faxed to the company, to the attention of: Ron Kalfus, Chief Financial Officer, at ir@mdxhealth.com and fax +32 4 259 78 75.

Ordinary and Extraordinary General Shareholders’ Meetings (May 27, 2021) | Assemblées Générales Ordinaire Et Extraordinaire Des Actionnaires (27 Mai 2021)

Convening Notice (EN) | Invitation (FR)

Attendance Form (EN) | Formulaire de Participation (FR)

Proxy Form (EN) | Formulaire de Procuration (FR)

Voting by mail Form (EN) | Formulaire de Vote par Correspondance (FR)

Outstanding Shares and Voting Rights (EN) | Actions et Droits de Votes en Circulation (FR)

Comptes Annuels Statutaires (non consolidés) (FR)

2020 Annual Report – Consolidated Financial Statements (EN) | Comptes Annuels Consolidés (FR)

Rapport Annuel du Conseil d’Administration sur les Comptes Annuels Statutaires (non consolidés) (FR)

Annual Report of the Board of Directors on the Consolidated Financial Statements (EN) | Rapport Annuel du Conseil d’Administration sur les Comptes Annuels Consolidés (FR)

Report of the Statutory Auditor on the (non-consolidated) Statutory Financial Statements (EN) | Rapport du Commissaire sur les Comptes Annuels Statutaires (non consolidés) (FR)

Report of the Statutory Auditor on the Consolidated Financial Statements (EN) | Rapport du Commissaire sur les Comptes Annuels Consolidés (FR)

Remuneration Policy (EN) | Politique de Rémunération (FR)

Special Board Report in Accordance with Article 7:199 of the Belgian Companies and Associations Code (EN) | Rapport Spécial du Conseil d’administration Conformément à l’Article 7:199 du Code des Sociétés et des Associations (FR)

Board Report in relation to the 2021 Share Option Plan (EN) | Rapport du Conseil d’Administration sur le Plan d’Option sur Action de 2021 (FR)

Auditor Report in relation to the 2021 Share Option Plan (EN) | Rapport du Commissaire sur le Plan d’Option sur Action de 2021 (FR)

2021 Share Option Plan (EN) | Plan d’Option sur Action de 2021 (FR)